A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
Clinical trial NCT06577025 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06577025
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-20
- Primary completion
- 2030-09-02
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.